Vera Therapeutics, Inc. - VERA STOCK NEWS

Vera Therapeutics (Nasdaq: VERA) announced promising new clinical data for atacicept, its lead product candidate, during the ERA-EDTA Congress. The investigational therapy demonstrated its ability to reduce both circulatory Gd-IgA1 and anti-Gd-IgA1 autoantibodies, which are linked to IgA nephropathy progression. In a Phase 2a trial, atacicept showed a significant decrease in anti-Gd-IgA1 levels, with reductions of up to 39% at 72 weeks. A post-hoc analysis from a Phase 2 study indicated potential renal function improvement in systemic lupus erythematosus patients. The company is advancing atacicept through further clinical trials.

Vera Therapeutics (VERA) remains on track with its Phase 2b ORIGIN clinical trial for atacicept, with topline data anticipated in Q4 2022. A Phase 3 trial for lupus nephritis is set to begin in the second half of 2022, following positive FDA interactions. The company boasts a robust balance sheet with approximately $151 million in cash and a $45 million credit facility, expected to fund operations through Q2 2024. Despite a net loss of $17.1 million for Q1 2022, the company continues to advance its clinical pipeline and maintain strong enrollment in its studies.

Vera Therapeutics (Nasdaq: VERA) announced participation in two key conferences in May 2022. The first is the LifeSci Partners Immunology & Inflammation Symposium on May 10, from 2:30-2:55 PM ET, featuring a fireside chat format. The second is the H.C. Wainwright Global Investment Conference from May 23-26, with a presentation scheduled for May 25, 1:30-2:00 PM ET. Both events will have live audio webcasts available online. Vera focuses on transformative treatments for serious immunological diseases, including its lead candidate, atacicept.

Vera Therapeutics (Nasdaq: VERA) announced two significant oral presentations of clinical data for its lead candidate, atacicept, at the upcoming ERA-EDTA Congress from May 19-22, 2022, in Paris. The presentations will include results from the Phase 2a JANUS trial on IgA nephropathy and a post-hoc analysis of the APRIL-SLE study in systemic lupus erythematosus. Atacicept, a weekly subcutaneous injection, targets B-cell activity linked to autoimmune diseases and has shown promising results in clinical studies.

Vera Therapeutics, Inc. (NASDAQ: VERA) announced that interim data from its Phase 2 trial of MAU868 versus placebo for treating BK Virus (BKV) in kidney transplant patients will be shared in a late-breaking presentation at the American Transplant Congress (ATC) 2022 on June 4, 2022. The trial aims to assess MAU868's safety and efficacy and represents a significant step in addressing BKV, a serious complication for transplant recipients. Vera holds exclusive worldwide rights for MAU868, acquired from Amplyx Pharmaceuticals, a Pfizer subsidiary.

Vera Therapeutics (Nasdaq: VERA) has appointed Michael M. Morrissey, Ph.D., as chairman of its board of directors. Dr. Morrissey, former president and CEO of Exelixis, brings extensive biopharmaceutical experience and expertise in drug development, regulatory processes, and commercialization. His leadership is expected to guide Vera as it transitions from late-stage clinical programs to commercialization efforts. The company focuses on innovative treatments for serious immunological diseases, including its lead candidate atacicept for IgA nephropathy and lupus nephritis.

Vera Therapeutics (Nasdaq: VERA) reports significant progress in its clinical pipeline, including the Phase 2b ORIGIN trial for atacicept, expecting topline data in Q4 2022. The company strengthened its financial position with an $80.2 million equity offering and plans a Phase 3 trial for atacicept in lupus nephritis. Furthermore, the acquisition of MAU868 aims to treat BK Virus infections, with interim results expected mid-2022. Vera ended 2021 with $79.7 million in cash, showing a reduced net loss of $16.8 million for Q4 2021, compared to $42.9 million the previous year.

Vera Therapeutics will host a KOL webinar on March 29, 2022, discussing its lead asset MAU868, a monoclonal antibody targeting BK Virus (BKV) infections in kidney transplant patients. Renowned nephrologist Dr. Stanley C. Jordan will present, emphasizing that BKV is a major cause of transplant-related complications. MAU868 is currently in a Phase 2 trial, showing promising results in lowering BK plasma viral load. There are no approved BKV treatments in the U.S., making this development critical for transplant care.

Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company, will host a business update call on March 24, 2022, at 8:00 a.m. ET. The company is focused on developing transformative treatments for serious immunological diseases. Investors can participate via a toll-free number or an international line, and a webcast will be available 15 minutes prior to the call. Vera's lead candidate, atacicept, targets autoimmune diseases such as IgA nephropathy and lupus nephritis. For details, visit www.veratx.com.